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We investigated the phenotypic and genetic properties of metallo--lactamase-producing Pseudomonas
isolates collected at a tertiary-care hospital in Korea since 1995. The prevalence of imipenem resistance among
Pseudomonas aeruginosa isolates reached 16% in 1997, when 9% of the resistant organisms were found to
produce VIM-2 -lactamase, a class B enzyme previously found only in P. aeruginosa isolates from Europe.
VIM-2-producing isolates of Pseudomonas putida were also detected. Resistance was transferable from both
these species to P. aeruginosa PAO4089Rp by filter mating, although the resistance determinant could not be
found on any detectable plasmid. Serotyping showed that many of the VIM-2-producing P. aeruginosa isolates
belonged to serotypes O:11 and O:12, and pulsed-field gel electrophoresis of XbaI-digested genomic DNA
revealed that many had identical profiles, whereas the P. putida isolates were diverse. Sequencing showed that
the blaVIM-2 genes resided as cassettes in class 1 integrons. In contrast to previous VIM-encoding integrons, the
integron sequenced from a P. aeruginosa isolate had blaVIM located downstream of a variant of aacA4. blaVIM
also lay in a class 1 integron in a representative P. putida strain, but the organization of this integron was
different from that sequenced from the P. aeruginosa strain. In conclusion, the metallo--lactamase produced
by these imipenem-resistant Pseudomonas isolates was VIM-2, and the accumulation of producers reflected
clonal dissemination as well as horizontal spread. Strict measures are required in order to control a further
spread of resistance.
Carbapenems such as imipenem are stable to most -lac-
tamases. Nevertheless, the first isolate of Pseudomonas aerugi-
nosa with transferable imipenem resistance due to a metallo-
-lactamase production was reported in Japan in 1991 (26).
The enzyme produced by this isolate almost certainly was
IMP-1, which subsequently has been repeatedly found in Ja-
pan, not only in P. aeruginosa and Acinetobacter baumannii
(23), but also in Serratia marcescens (14) and other members of
Enterobacteriaceae (5). Rasmussen and Bush (18) predicted
that the increasing use of carbapenems would select for more
carbapenem-hydrolyzing organism on a wider scale, and this
prediction is now proving correct. Several close relatives of
IMP-1 have been reported during the past 3 years: IMP-2 from
an isolate of A. baumannii in Italy (19), IMP-3 (MET-1) from
Shigella flexneri in Japan (6), and IMP-4 from Acinetobacter
and Citrobacter spp. from Hong Kong, China (3).
Descriptions of IMP-5 to IMP-8 enzymes are understood to
be in press. IMP-1 to IMP-4 have at least 80% homology to
each other, but in 1999, a new type of acquired metallo--lac-
tamase, VIM-1, was reported to have been found in an isolate
of P. aeruginosa collected in Italy (8). Soon afterwards, isolates
of P. aeruginosa with a related enzyme, VIM-2, were reported
in France (16, 17). Since then, outbreaks of VIM -lactamase-
producing P. aeruginosa have been reported in Greece (25) and
Italy (4).
Although the VIM and IMP metallo--lactamase have only
30 to 40% amino acid homology, both are often encoded by
mobile gene cassettes inserted into integrons (1, 8, 17), which
are sometimes located on plasmids. Most of these integrons
belong to class 1, but their structures vary among isolates.
In the present study, we determined the phenotypes and
genetic properties of metallo--lactamase-producing Pseudo-
monas strains collected at one hospital in Korea since 1995.
(This study was presented, in part, at the 38th Interscience
Conference on Antimicrobial Agents and Chemotherapy [K.
Lee, Y. Chong, H. B. Shin, and D. Yong, Abstr. 38th Intersci.
Conf. Antimicrob. Agents Chemother., abstr. E-85, 1998] and
at the 40th Interscience Conference on Antimicrobial Agents
and Chemotherapy [K. Lee, J. B. Lim, J. H. Yum, D. Yong,
J. R. Choi, Y. Chong, and J. M. Kim, Abstr. 40th Intersci.
Conf. Antimicrob. Agents Chemother., abstr. 2003, 2000].)
MATERIALS AND METHODS
Bacterial strains and susceptibility testing. Nonduplicate isolates of Pseudo-
monas spp. were from clinical specimens from patients in a tertiary-care hospital
in Seoul, Korea. The species were identified by conventional methods (7) and
with the ID 32 GN system (bioMerieux, Marcy-l’Etoile, France). Imipenem
resistance was initially detected by a disk diffusion method (13), and the resistant
isolates were kept in skim milk at 76°C until used for further testing. The MICs
of antimicrobial agents were determined by an agar dilution method (12). The
agents and -lactamase inhibitors used were ampicillin and cephalothin (Sigma,
St. Louis, Mo.), cefoxitin and imipenem (Merck/Sharp & Dohme, Rahway, N.J.),
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meropenem (Sumitomo, Tokyo, Japan), cefotaxime (Aventis, Frankfurt, Ger-
many), ceftazidime and clavulanic acid (GlaxoSmithKline, Greenford, United
Kingdom), piperacillin and tazobactam (Wyeth, Pearl River, N.Y.), aztreonam
(Bristol-Myers Squibb, Princeton, N.J.), amikacin and kanamycin (Dong-A Phar-
maceutical, Seoul, Korea), gentamicin (Chong Kun Dang Pharmaceutical, Seoul,
Korea), streptomycin (Meiji Seika, Tokyo, Japan), tobramycin (Daewoong-Lilly,
Seoul, Korea), and ciprofloxacin (Bayer Korea, Seoul, Korea). Metallo--lac-
tamase production was screened with modified Hodge and EDTA disk synergy
tests (9).
Conjugation. The filter mating method (20) was used to determine the trans-
ferability of the carbapenem resistance determinant using the rifampin-resistant
mutant P. aeruginosa, PAO4089Rp (26) as a recipient. Mueller-Hinton agar
containing 100 g of rifampin per ml and 2 g of imipenem per ml was used to
select transconjugants.
Serotyping, plasmid preparation, PFGE of genomic DNA, and hybridization.
O serotypes of the P. aeruginosa isolates were determined by a slide-agglutination
method of the International Antigenic Typing Scheme. Plasmids were isolated by
alkaline lysis (21). For pulsed-field gel electrophoresis (PFGE), XbaI-digested
genomic DNA was prepared according to the instruction of Bio-Rad (Hercules,
Calif.) and fragments were separated for 20 h at 6 V/cm at 11°C using a
CHEF-DR II System (Bio-Rad), with initial and final pulse times of 0.5 and 30 s,
respectively. DNA fingerprints were compared visually and were interpreted as
recommended by Tenover et al. (24).
For Southern hybridization, plasmid or genomic DNA was transferred from
electrophoresis gels to nylon membranes using a Trans-Blot SD Semi-Dry Trans-
fer Cell (Bio-Rad). A DIG DNA Labeling and Detection Kit (Roche Diagnos-
tics, Mannheim, Germany) was used to label the blaVIM-2 probe and for hybrid-
ization.
-Lactamase assays and isoelectric focusing. The -lactamase activities of cell
sonicates from overnight Luria-Bertani broth cultures were determined using a
spectrophotometer (UV-1601PC; Shimadzu Corp., Tokyo, Japan) with a 100 M
solution of -lactams in 50 mM phosphate buffer (pH 7.0) at 30°C. The wave-
lengths used were 235 nm for benzylpenicillin (Sigma) and 297 nm for both
imipenem and meropenem (11). The protein content of the sonicates was de-
termined with a commercial assay reagent (Bio-Rad).
The isoelectric points of -lactamases were determined by loading cell soni-
cates to precast pH 3 to 10 gels (Novel Experimental Technology, San Diego,
Calif.). These were electrophoresed on a ThermoFlow Electrophoresis Temper-
ature Control System (Novel Experimental Technology). After electrophoresis,
the gels were overlaid with filter papers soaked in 0.7 mg of nitrocefin per ml in
a 30 mM N-(2-acetamido)-2-aminoethanesulfonic acid–NaOH buffer (pH 7.0)
(8). Sonicates of Escherichia coli and P. aeruginosa VR-143/97 (8) producing
TEM-1 (pI 5.4) and VIM-1 (pI 5.3) -lactamases, respectively, were used as
controls. Imipenem-hydrolyzing bands were confirmed by observation for growth
when the gel was overlaid with Mueller-Hinton agar containing E. coli ATCC
25922 and 2 g of imipenem per ml and then incubated overnight at 37°C. The
gels were overlaid with a filter paper soaked in 20 mM EDTA for 5 min before
the imipenem-containing agar was added so that inhibition of imipenem-hydro-
lyzing activities could be observed.
Detection of metallo--lactamase genes by PCR. Previously reported PCR
primers were used to determine the presence of blaIMP (2) and blaVIM-2 (17).
PCR was carried out with 1 l of heat-extracted template DNA, 20 pmol of each
primer, and PreMix (Bioneer, Cheongwon, Korea) containing 1 U of Taq DNA
polymerase in a total volume of 20 l. A thermal cycler (Eppendorf-Netheler-
Hinz, Hamburg, Germany) was used under the following conditions: 94°C for
5 min, 25 cycles of 94°C for 30 s, 56°C for 30 s, and 72°C for 45 s, followed by 72°C
for 7 min. The bands were confirmed by hybridization with a blaVIM-2 probe.
Sequencing the blaVIM-containing integron. PCR products were obtained by
the hot-start method in a total volume of 100 l, with 5 l of heat-extracted
template DNA, 20 pmol of primers INT/5CS and INT/3CS (19), and 3 U of LA
Taq DNA polymerase (Takara, Shiga, Japan). The reaction conditions consisted
of a predenaturation at 94°C for 12 min and then 35 cycles of 94°C for 1 min,
56°C for 1 min, and 72°C for 5 min. The extension time was increased by 5 s at
each cycle, as described by Levesque and Roy (10).
The PCR products were ligated in the pGEM-T Easy Vector (Promega,
Madison, Wis.) and transformed into E. coli DH5 by electroporation using an
E. coli Pulser (Bio-Rad) (22). Successful clones were selected by the observation
of decreased imipenem disk zones. Plasmids from cloned strains were used to
sequence blaVIM and the other cassettes in the integrons, using the dideoxy-chain
termination method with an ABI 3700 Autosequencer and the reagents supplied
by its manufacturer (Perkin-Elmer, Foster City, Calif.). Primers INT/5CS and
INT/3CS were those reported previously (19). The nucleotides of custom-de-
signed primers were as follows: INT7-R, 5-GTT CTT CTA CGG CAA GGT
GC-3 (bp 261 to 280); VIM-2-F, 5-ATT GGT CTA TTT GAC CGC GTC-3
(bp 55 to 75); VIM-2-R, 5-TGC TAC TCA ACG ACT GAG CG-3, (bp 784 to
803); VIM-2b-F, 5-CAA CAA CAC TAC CCG GAA GC-3, (bp 679 to 698),
VIM-2a-R, 5-ATC TGG TAA AGC CGG ACC TC-3 (bp 127 to146); AAC6-F,
5-ACT GAG CAT GAC CTT GCA AT-3 (bp 4 to 23), AAC6-R, 5-CTG GCG
TGT TTG AAC CAT GT-3 (bp 470 to 489); AACA7-F, 5-AGC ATT GGG
CTC GTG GTC G-3 (bp 323 to 341); AACA7-R, 5-GAC ACC TCC GTG
AAT CCA G-3 (bp 410 to 428); AADA1-F, 5-TGA TTT GCT GGT TAC GGT
GAC-3 (bp 144 to 164); AADA1-R, 5-CAC TAC ATT TCG CTC ATC G-3
(bp 543 to 561); ORF1-F, 5-GAC TTC TGG GCG TTC ATT GG-3 (bp 257 to
276); ORF2a-R (5-TGG CGA CAA GGT GAA AGA C-3 (bp 486 to 504);
ORF2b-R, 5-TGG CTA TCA GCA CTG CGT TGA G-3 (bp 1002 to 1023);
ORF2c-F, 5-ATC CAG CTC AAC GCA GTG CTG AT-3 (bp 1007 to 1029);
ORF3-R, 5-AGA AGC CAA ACG CCC ATC GTA-3 (bp 1 to 21 upstream
from orf “iii”) (Fig. 2). The determination of the sequences was repeated with
more than two clones from independent amplicons. Also, the sequences on both
strands were determined.
Nucleotide sequence accession numbers. The nucleotide sequences reported
have been assigned the GenBank accession nos. as follows: for the integron from
P. aeruginosa YMC 95/1/704, AY029772; for P. putida YMC 97/8/322, AF327064.
RESULTS
Prevalence of imipenem resistance and metallo--lactamase
producer. In 1995, 3% of P. aeruginosa isolates at the hospital
were imipenem resistant, and among the resistant isolates ex-
amined, five had metallo--lactamases. Of eight imipenem-
resistant P. aeruginosa collected in 1996, none had metallo--
lactamases. In 1997, however, the prevalence of imipenem
resistance rose to 16% and among the total of 130 imipenem-
resistant isolates 11.5% had metallo--lactamases (Table 1).
The prevalence rate of imipenem resistance in P. aeruginosa
then stabilized, as did the proportion with metallo--lactam-
ases. Metallo--lactamase-producing P. putida isolates were
TABLE 1. Trend of isolation of imipenem-resistant Pseudomonas spp. and detection of blaVIM-2-positive isolates
Yr
P. aeruginosa P. putida
No. of isolates
(% imipenem resistance)
No. of blaVIM-2 isolates No. of isolates
(% imipenem resistance)
No. of blaVIM-2 isolates
Tested Positive (%) Tested Positive (%)
1994 1,939 (4) 1 0 (0) 38 (8) 0 NAa
1995 966 (3) 20 5 (25.0) 6 (0) 0 NA
1996 2,189 (6) 8 0 (0) 37 (16) 0 NA
1997 2,078 (16) 130 15 (11.5) 17 (6) 1 1 (100)
1998 2,934 (15) 147 12 (8.2) 35 (29) 5 5 (100)
1999 3,129 (15) 187 11 (5.9) 35 (17) 3 3 (100)
Total 13,235 (11) 493 43 (8.7) 168 (15) 9 9 (100)
a NA, not applicable.
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first detected in 1997. PCR showed that all of the metallo--
lactamase producers had blaVIM-2 but none had blaIMP-1.
Isoelectric focusing of extracts of the blaVIM-2-positive iso-
lates detected a -lactamase with a pI of ca. 5.3, which was no
longer apparent if the gels were overlaid with EDTA. A bio-
logical assay showed that this pI 5.3 band inactivated imi-
penem, allowing the growth of the E. coli indicator strain in an
agar overlay. Almost all of the blaVIM-2-positive isolates also
had other -lactamase bands with pIs of ca. 7 to 8.
Among the total of 52 blaVIM-2-positive P. aeruginosa and P.
putida isolates collected, 35 (67%) were from urines, 10 (19%)
were from sputa, and 2 (4%) were from blood samples; among
the 9 P. putida isolates all except one were from urine. Most of
the source patients had underlying malignancy, recent brain
surgery, indwelling urinary catheters, prior therapy with vari-
ous antimicrobial agents, and/or admission to intensive care
units (data not shown).
Conjugative transfer of resistance. Carbapenem resistance
was transferred from 6 of the 43 P. aeruginosa isolates and 2 of
the 9 P. putida isolates with blaVIM-2 to a P. aeruginosa recip-
ient. However, repeated attempts failed to detect the presence
of plasmids capable of hybridizing with the blaVIM-2 probe,
while the fragments of the XbaI-digested genomic DNA of
clinical isolates showed hybridization. Resistances to cipro-
floxacin and amikacin were not transferred to the transconju-
gants.
Susceptibilities of isolates and transconjugants. MIC ranges
of imipenem for blaVIM-2-positive clinical isolates and trans-
conjugants of P. aeruginosa were 8 to 128 and 16 to 32 g/ml,
respectively; those for P. putida isolates and transconjugants
were 16 to 128 and 16 to 32 g/ml, respectively (Table 2). MICs
of imipenem and meropenem for the P. aeruginosa recipient
were 0.25 and 0.5 g/ml, respectively. MICs of all of the other
-lactams for clinical isolates were 32 g/ml, except for az-
treonam, whose MICs were as low as 4 g/ml for some isolates.
A slight reduction in the MICs of piperacillin was achieved
in the presence of tazobactam (4 g/ml), but the MICs of
cefotaxime were not reduced by clavulanic acid. Most of the
VIM-2-producing P. aeruginosa isolates were also resistant to
gentamicin, tobramycin, and ciprofloxacin.
Serotype and PFGE profile. PFGE of XbaI-digested geno-
mic DNA from blaVIM-2-positive P. aeruginosa showed that 26
isolates gave an identical pattern, E1 (Fig. 1). Among these, 11
strains were isolated from 1997 to 1999: 6 serotype O:11 iso-
lates were from two each of pediatric and neurosurgery pa-
tients and from one each of gynecology and rehabilitation
patients; 5 O polyagglutinating (OPA) isolates were from two
internal medicine patients and from one each of pediatric,
rehabilitation, and neurosurgery patients. Among the six iso-
lates with PFGE pattern C2, five were serotype O:12 and were
isolated from four ICU patients in 1997 and one pediatric
patient in 1995. Among the six isolates of P. aeruginosa that
were gene transfer positive, four had PFGE pattern C2 with
serotype O:12. The remaining two serotype OPA isolates had
PFGE patterns A and D1. Eight different PFGE profiles were
seen among the nine blaVIM-2-positive P. putida isolates.
Biochemical detection of VIM -lactamases. Cell sonicates
of all blaVIM-2-positive isolates hydrolyzed imipenem in spec-
trophotometric assays; this activity was inhibited by EDTA,
but not by clavulanic acid. Using extracts of a representative
P. aeruginosa strain, relative hydrolysis rates of 100 M ben-
zylpenicillin, imipenem, and meropenem were in a 100:21:7
ratio. With extracts of a P. putida isolate this ratio was 100:2:
1, reflecting a relatively higher background penicillinase ac-
tivity. Imipenem-hydrolyzing activities of the P. aeruginosa and
P. putida extracts were 96 and 61 U per mg of protein, respec-
tively (data not shown).
Sequences of blaVIM-2 and flanking genes. PCR products of
the integron carrying blaVIM-2 were detected from 41 of the 43
P. aeruginosa and all of the 9 P. putida isolates. The sizes of the
integrons carrying the blaVIM-2 varied among the isolates, from
ca. 3 to 6 kb, but in 23 of 50 isolates they were ca. 5 kb. The
sizes in the 25 P. aeruginosa strains with PFGE pattern E1 were
ca. 4 kb in 6 isolates, 5 kb in 15 isolates, and 6 kb in 4 isolates.
The first isolates of P. aeruginosa and P. putida were chosen to
analyze the nucleotide sequence of the blaVIM allele and its
TABLE 2. Antimicrobial susceptibilities of blaVIM-2-positive clinical isolates and their transconjugants
Antimicrobial agenta
P. aeruginosa P. putida
CIb (n 	 43) TCb (n 	 6) CI (n 	 9) TC (n 	 2)
MIC rangec MIC50c MIC90c MIC range MIC range MIC range
Imipenem 8–128 16 128 16–32 16–128 16–32
Meropenem 8–128 16 128 8–32 32–128 8–16
Piperacillin 64–256 256 256 8–128 64–256 256
Piperacillin-tazobactamd 32–128 128 128 8–128 32–256 128
Cefotaxime 128 128 128 64–128 128 128
Cefotaxime-clavulanic acidd 128 128 128 32–128 128 128
Ceftazidime 32–128 128 128 8–64 32–128 128
Aztreonam 4–64 16 32 2–4 16–32 4
Amikacin 2–128 128 16 4 16–128 4
Gentamicin 8–128 128 128 64 32–128 64
Kanamycin 64–128 128 128 128 16–128 128
Streptomycin 128–128 128 128 128 128 128
Tobramycin 2–128 128 32 16–32 16–128 32
Ciprofloxacin 0.12–128 32 16 0.12–0.25 16 0.12
a MICs of ampicillin, cephalothin, and cefoxitin for all of the strains were 128 g/ml.
b Abbreviations: CI, clinical isolates; TC, transconjugants.
c Values are in micrograms per milliliter; MIC50 and MIC90, MICs for 50 and 90% of strains, respectively.
d Piperacillin-tazobactam: tazobactam at a fixed concentration of 4 g/ml; cefotaxime- clavulanic acid: a 2:1 combination.
VOL. 46, 2002 blaVIM-2 CASSETTES IN PSEUDOMONAS SPP. 1055
flanking genes. Analysis revealed sequences of blaVIM-2 in both
cases. The structure of the integron from the P. aeruginosa
isolate was aacA4 [Asp1713Val variant of aac(6)-II], fol-
lowed immediately downstream by blaVIM-2; in addition aadA1
was present. The integron from the P. putida isolate differed in
that the first cassette was blaVIM-2 followed by aacA7 and
aadA1 (Fig. 2).
DISCUSSION
The frequency of imipenem resistance among P. aeruginosa
isolates at the hospital rose to 16% in 1997, thereafter stabi-
lizing. Approximately 9% of the resistance isolates were me-
tallo--lactamase-producers, and all these had blaVIM-2 (Table
1). In another study in 1999 (K. Lee, H. S. Lee, S. H. Kang,
M. H. Lee, W. K. Song, S. J. Kim, and Y. Chong, Abstr. 7th
Western Pacific Cong. Chemother. Infect. Dis., abstr. FP2.8,
2000), it was found that blaVIM-2-positive P. aeruginosa isolates
were widespread in other Korean hospitals too, being detected
in 9 of 29 hospitals surveyed, with an overall prevalence rate of
11.9% among imipenem-resistant P. aeruginosa isolates. As
reported here, blaVIM-2 has also spread to P. putida in a Ko-
rean hospital.
It is striking that the metallo--lactamase found in Korea is
not the IMP-1 type which is scattered in Japan, but the VIM
type, which was previously reported only from Europe (8, 17).
Moreover, although VIM-1 and VIM-2 -lactamase-producing
P. aeruginosa isolates were collected in 1996 and 1997 in Eu-
rope, it is now clear that VIM-2 producers have existed in Ko-
rea since 1995 and have become much more widespread than
has been observed elsewhere. Most of the present blaVIM-2-
positive isolates were P. aeruginosa, but nine were P. putida.
The P. aeruginosa isolates were mostly from urines and sputa,
indicating that these were important sources of the spread.
PFGE of XbaI-digested genomic DNA showed that many of
these organisms clustered to patterns C2 and E1. Serotyping
showed that all members of the former group tested were
serotype O:12, whereas those of the latter were either serotype
O:11 or serotype OPA. These data imply a major role for
clonal spread. It is interesting that VIM-producing P. aerugi-
nosa isolates reported in Greece (25) were also serotype O:12,
which is otherwise a rare type. The occurrence of blaVIM-2 in
different PFGE and serotypes, as well as in two different
Pseudomonas species in the present study, indicated horizontal
spread, too. Only two of nine P. putida isolates shared an iden-
tical PFGE profile, suggesting a much greater role for hori-
zontal spread in the latter species (data not shown). Moreover,
an ongoing study has revealed the presence of blaVIM-2 in Acin-
etobacter and Serratia spp. from Korea.
In earlier studies, blaIMP has been found to be located on
conjugative plasmids (26), but blaVIM-2 has not previously been
found on self-transferable elements (17), while the blaVIM-1
gene was located on the chromosome in the sole producer
studied (8). Initial attempts, using an E. coli recipient, to trans-
fer blaVIM-2 from the present isolates were unsuccessful. Nev-
ertheless, we were able to transfer the resistance from six
P. aeruginosa and two P. putida isolates by using P. aeruginosa
PAO4089Rp as a recipient. Repeated attempts to detect
blaVIM on plasmids were unsuccessful with both the isolates
and the transconjugants. Rather, fragments of genomic DNA
separated by PFGE hybridized with a gene probe for blaVIM-2,
suggesting a chromosomal location. We cannot, however, ex-
FIG. 1. Schematic presentation of PFGE patterns of XbaI-digested genomic DNA of blaVIM-2-positive isolates of P. aeruginosa. M in lane 1 is
a size marker (a chromosome of Saccharomyces cerevisiae). The numbers of isolates with serotypes O:11, O:12, and OPA are shown under each
PFGE profile, and total numbers are in parentheses. OPA, O polyagglutination; NT, serotype not tested.
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clude possible carriage by a large plasmid that associated
strongly with the chromosome. MICs of imipenem for the
present isolates of P. aeruginosa ranged from 8 to 128 g/ml,
with an MIC50 of 16 g/ml. Variations in the level of resistance
may depend on the amount of VIM enzyme or on the perme-
ability of the isolates. Not all VIM-2-producing isolates there-
fore would be categorized as imipenem resistant when using
the NCCLS resistance breakpoint of16 g/ml. This situation
recapitulates that seen with some extended-spectrum -lactam-
ase-producing isolates of E. coli and Klebsiella pneumoniae,
which appear susceptible to extended-spectrum cephalosporins
at NCCLS breakpoints (12).
Most of our VIM-2-producing P. aeruginosa isolates were
also resistant to most aminoglycosides and ciprofloxacin, cre-
ating a serious problem for the choice of therapy. However,
carbapenemase-producing P. aeruginosa isolates are suscepti-
ble to aztreonam because there is poor hydrolysis (18).
It was reported elsewhere that the pI of VIM-2 -lactamase
was 5.6 rather than 5.3 (17); in our experience, however, it was
difficult to obtain sharp metallo--lactamase bands from cell
sonicates as reported also for Stenotrophomonas maltophilia
(15) and repeated analysis found that the pI of VIM-2 was
indistinguishable from that of the VIM-1 control, which was
run in parallel.
Our initial attempts directly to sequence the PCR products
of integrons were unsuccessful due to the presence of another
integron. Therefore, we used cloned strains. The nucleotide
sequences of the blaVIM-2 alleles from our P. aeruginosa and
P. putida strains were identical to each other and to that of the
original VIM-2 producer, P. aeruginosa COL-1 (17). The struc-
ture of the integron in our P. aeruginosa strain was different
from that in strain COL-1, which contained only the VIM-2
cassette (17), and was more similar to those in strains RON-1
and RON-2 (16), which also contained other cassettes besides
blaVIM-2. However, the first cassette at the 5 end of the inte-
gron from our P. aeruginosa strain was different from previ-
ously described aacA7 (strain RON-1) or aacA29a (RON-2)
(16) in that it was a variant of aacA4, conferring resistance to
gentamicin, tobramycin, and kanamycin, but not to amikacin.
Also, downstream of the blaVIM-2, aadA1 was present rather
than aacC1 and aacA4 (strain RON-1) or aacA29b (RON-2).
Furthermore, unknown orf “i,” orf “ii,” and orf “iii” occupied a
large space between blaVIM-2 and qacE
1. Strangely, repeated
sequencing showed that the unknown orf “ii” lay in a reversed
orientation, which would preclude its expression under the
single promoter of the integron structure. The integron from
the P. putida strain was different in that the first cassette was
blaVIM-2 and that aacA7 was present along with aadA1 and
qacE
1.
In conclusion, the metallo--lactamase produced by these
P. aeruginosa isolates, collected in Korea since 1995, was
VIM-2 and this enzyme and its contingent resistance have also
reached P. putida. This is the first report of VIM-2 -lactamase
outside Europe and the first report for P. putida worldwide.
The blaVIM-2 gene resided on two novel class 1 integrons. The
persistence and spread of VIM-2-mediated resistance reflected
clonal as well as horizontal spread. Stricter measures are re-
quired to control its further spread in Korea and elsewhere.
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